Table 1.
The characteristics of included studies, according to intervention group (curcumins) and control groups (placebo) and results for each selected outcome.
| Author, Year, Country |
Mean Age |
Male % |
Diabetes Duration (Years) |
Groups | BMI Variation Mean (SD) |
HOMA-IR | Hb1Ac Mean (SD) |
TG Mean (SD) |
TC Mean (SD) |
HDL Mean (SD) |
LDL Mean (SD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hodaei 2019 Iran [10] |
59 | 50 | 1–10 | Intervention Group N = 21 (1500 mg) |
29.2 (3.76) 28.9 (3.73) |
62 (63) 62.4 (42) |
11.3 (1.6) 11 (2.0) |
- | - | - | - |
| Control Group N = 23 |
28.2 (2.5) 28.1 (2.5) |
53 (40) 65 (44) |
11.2 (1.3) 11.1 (1.8) |
- | - | - | - | ||||
| Adibian 2019 Iran [11] |
59 | 50 | 1–10 | Intervention Group N = 21 (1500 mg) |
- | - | - | 124 (36) 109 (36) |
167 (34) 163 (39) |
30 (2) 30 (2) |
112 (31) 108 (36) |
| Control Group N = 23 |
- | - | - | 126 (52) 121 (44) |
180 (47) 175 (47) |
30 (2) 30 (2) |
125 (44) 118 (47) |
||||
| Adab 2018 Iran [12] | 55 | 51 | 5–10 | Intervention Group N = 39 (2100 mg) |
28.98 (3.68) 28.26. (3.45) |
2.42 (1.73) 2.21 (1.43) |
7.06 (1.01) 7.04 (0.98) |
181.56 (79.9) 141.74 (52.02) |
148.85 (36.11) 149.82 (35.67) |
38.79 (10.30) 37.07 (9.12) |
82.56 (20.99) 75.23 (18.84) |
| Control Group N= 36 |
28.82 (4.96) 28.68 (4.86) |
2.24 (1.48) 2.69 (2.02) |
6.79 (1.08) 7.28 (1.59) |
164.05 (81.19) 197.05 (96.98) |
155.36 (36.27) 176.88 (37.58) |
44.63 (10.66) 42.11 (9.39) |
86.61 (21.99) 89.05 (21.46) |
||||
| Rahimi 2015 Iran [13] |
58.64 | 45 | NR | Intervention Group (80 mg) N = 35 |
26.92 (2.71) 25.57 (2.71) |
- | 7.59 (1.74) 7.31 (1.54) |
109 (94.75) 131 (60.27) |
163.4 (33.94) 158.62 (44.06) |
54.30 (14.02) 60.95 (15.68) |
96.57 (33.94) 91.04 (28.72) |
| Control Group N = 35 |
27.27 (3.59) 27.50 (3.38) |
- | 7.49 (1.75) 9.05 (2.33) |
142 (97.5) 113 (58) |
85.5 (15.3) 80.5 (9.1) |
60.35 (15.96) 55.00 (11.09) |
98.78 (30.33) 99.78 (30.33) 84.00 (12.59) |
||||
| Chuengsamarn Thailand 2014 [14] |
59 | 48 | 12 | Intervention Group N = 107 |
- | 9.58 (4.3) 4,32 (1.8) |
- | 219.12 (97.52) 141.99 (67.79) |
- | - | - |
| Control Groups N = 106 |
- | 6.89 (2.67) 6.78 (2.5) |
- | 252.72 (114.12) 252 (114.12) |
- | - | - | ||||
| Na China 2013 [15] |
55.07 | 49 | 7.6 | Intervention Group (300 Mg) N = 50 |
- | 5.80 (3.35) 4.14 (1.81) |
7.77 (1.82) 7.02 (2.04) |
223.8 (46.8) 157.5 (49.5) |
540 (100) 493 (41.7) |
52.9 (10.04) 54.8 (11.2) |
166.0 (46.3) 146.7 (39.7) |
| Control Group N= 50 |
- | 5.82 (3.90) 5.49 (2.15) |
7.72 (2.12) 7.99 (2.86) |
193.8 (92.04) 186.7 (66.3) |
538 (109) 522 (105.3) |
51.35 (10.81) 51.74 (8.8) |
166.8 (44.4) 160.2 (45.17) |
||||
| Usharani India 2008 [16] |
52 | 8 | Intervention Group N = 23 (300 mg) |
- | - | 8.04 (0.85) 8.03 (0.76) |
176.39 (27.61) 165.26 (25.78) |
195.0 (41.16) 185.34 (34.35) |
38.78 (7.69) 39.91 (0.68) |
120.35 (42.13) 111.34 (37.65) |
|
| Control Group N= 21 |
- | - | 7.82 (0.57) 7.80 (0.62) |
170.14 (47.54) 168.14 (47.10) |
195.95 (35.72) 198.76 (35.09) |
36.38 (7.67) 37.04 (5.92) |
124.59 (34.94) 122.18 (35.56) |
%: Males enrolled in each study.TG: triglycerides, TC: total cholesterol.